HYCOR BIOMEDICAL INC /DE/
10-Q, EX-27, 2000-08-10
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: HYCOR BIOMEDICAL INC /DE/, 10-Q, 2000-08-10
Next: INRAD INC, 10-Q, 2000-08-10



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED
JUNE 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q
FOR THE QUARTER ENDED JUNE 30, 2000.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                         972,398
<SECURITIES>                                 1,774,793
<RECEIVABLES>                                3,055,109
<ALLOWANCES>                                   155,793
<INVENTORY>                                  4,349,525
<CURRENT-ASSETS>                            10,351,837
<PP&E>                                      10,803,527
<DEPRECIATION>                             (7,339,850)
<TOTAL-ASSETS>                              15,095,042
<CURRENT-LIABILITIES>                        4,016,941
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        74,368
<OTHER-SE>                                  10,949,578
<TOTAL-LIABILITY-AND-EQUITY>                15,095,042
<SALES>                                      8,931,577
<TOTAL-REVENUES>                             8,931,577
<CGS>                                        3,952,150
<TOTAL-COSTS>                                3,952,150
<OTHER-EXPENSES>                             4,442,621
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              48,641
<INCOME-PRETAX>                                489,852
<INCOME-TAX>                                    38,560
<INCOME-CONTINUING>                            489,852
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   489,852
<EPS-BASIC>                                       0.07
<EPS-DILUTED>                                     0.06


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission